

スリーエム ジャパン株式会社

2022年11月7日

3M、2022 年第3 四半期の業績を発表

当資料は、3M 社(本社:米国ミネソタ州、NYSE:MMM)が 2022 年 10 月 25 日(現地時間)に発表した報道資料を抄訳したものです。

第3四半期のハイライト

米国の GAAP ベースの一株当たり利益は 6.77 ドル

特別項目の影響を除いた調整後の一株当たり利益は 2.69 ドル

	2022	2021
	Q3	Q3
米国の GAAP ベースの一株当たり利益	\$6.77	\$2.45
特別項目:	(4.08)	0.13
調整後の一株当たり利益	\$2.69	\$2.58
備考:		
米国の GAAP ベースの営業利益率	48.2%	20.0%
調整後の営業利益率	21.5%	21.1%

当該情報については、以下の「連結財務諸表と補足財務情報:Non-GAAP 指標」を参照してください。

- 売上高は前年同期比 4%減少して 86 億ドルに(事業売却の影響によるマイナス 1 ポイント、 ドル高に伴う外貨換算の影響によるマイナス 5 ポイントを含む)
- 既存ビジネス※(Organic sales:事業売却や買収を除いた既存ビジネス)の売上高は前年同期 比 2%増加(使い捨て式呼吸用保護具の需要減の影響による逆風の 1.4 ポイントを含む)
- 営業活動によるキャッシュフローは前年同期比 18%減の 15 億ドル、調整後のフリーキャッシュフローは前年同期比 16%減の 14 億ドル
- 配当と自社株買いにより 10 億ドルを株主に還元
- フードセーフティ事業の売却に伴うエクスチェンジ・オファーによって、約 10 億ドルを対価 として受け取り、発行済み株式を 1,600 万株削減

3M が 2022 年第 3 四半期の業績を発表しました。

マイク・ローマン会長兼最高経営責任者は次のように述べています。

「非常に不透明な環境のなかでも、3M は引き続き戦略を実行し、お客様の期待に応えています。 使い捨て式呼吸用保護具の売上減による影響を除けば、今期は 3%を上回る有機的成長を遂げたこと になります。マクロ経済の課題やドル高の影響を受けながらも、引き続き、利益率を前年同期に比べ 増加させました。成長と生産性、そしてサステナビリティへの投資、ならびに積極的なポートフォリオ管理を通じて、3M の未来を切り開いていきます。今期は、フードセーフティ事業の売却を完了し、ヘルスケア事業の分社化の手続きを開始しました。分社化により、世界クラスの公開会社が 2 社誕生することになります。」

この度、ドル高の進行やマクロ経済環境の不透明さを踏まえて、2022 年通期の売上高・利益の予測を改めました。

- 売上高の成長見通し:従来の-2.5~-0.5%を-3.5~-3.0%に修正
- 既存ビジネス※(Organic sales:事業売却や買収を除いた既存ビジネス)の売上高の成長見通 し:従来の 1.5~3.5%を 1.5~2.0%に修正
- 事業の買収・売却による売上高の成長見通し:従来の0%を-0.5%に修正
- 外貨換算の売上高への影響:従来の-4.0%を-4.5%に修正
- 調整後の一株当たり利益:従来の 10.30~10.80 ドルを 10.10~10.35 ドルに修正
- 営業活動によるキャッシュフローは 68~74 億ドル、調整後のフリーキャッシュフローコン バージョンは 85~95%

当該情報については、以下の「連結財務諸表と補足財務情報:Non-GAAP 指標」を参照してください。その中でも詳しく述べられておりますが、3M は合理的な範囲を超えた努力をすることなしには、有意義かつ比較可能な GAAP 財務指標の策定に必要な特定の項目を予測することがでないため、こうした項目を反映した将来の見通しに基づいて当該財務指標を提示することも差し控えます。

連結財務諸表と補足財務情報:Non-GAAP 指標

連結財務諸表と補足財務情報:Non-GAAP 指標は、以下よりご覧いただけます(英語)。 https://investors.3m.com/Financial-Statements-Q322

Forward-Looking Statements

This news release contains forward-looking information about 3M's financial results and estimates and business prospects that involve substantial risks and uncertainties. You can identify these statements by the use of words such as "anticipate," "estimate," "expect," "aim," "project," "intend," "plan," "believe," "will," "should," "could," "target," "forecast" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business plans or prospects. Among the factors that could cause actual results to differ materially are the following: (1) worldwide economic, political, regulatory, capital markets and other external conditions and other factors beyond the Company's control, including natural and other disasters or climate change affecting the operations of the Company or its

customers and suppliers; (2) risks related to public health crises such as the global pandemic associated with the coronavirus (COVID-19); (3) foreign currency exchange rates and fluctuations in those rates; (4) liabilities related to certain fluorochemicals, including lawsuits concerning various PFAS-related products and chemistries, and claims and governmental regulatory proceedings and inquiries related to PFAS in a variety of jurisdictions; (5) legal proceedings, including significant developments that could occur in the legal and regulatory proceedings described in the Company's Annual Report on Form 10-K for the year ended Dec. 31, 2021, as updated by the Company's Current Report on Form 8-K dated April 26, 2022, and any subsequent quarterly reports on Form 10-Q (the "Reports"); (6) competitive conditions and customer preferences; (7) the timing and market acceptance of new product offerings; (8) the availability and cost of purchased components, compounds, raw materials and energy (including oil and natural gas and their derivatives) due to shortages, increased demand or supply interruptions (including those caused by natural and other disasters and other events); (9) unanticipated problems or delays with the phased implementation of a global enterprise resource planning (ERP) system, or security breaches and other disruptions to the Company's information technology infrastructure; (10) the impact of acquisitions, strategic alliances, divestitures, and other unusual events resulting from portfolio management actions and other evolving business strategies, and possible organizational restructuring; (11) operational execution, including scenarios where the Company generates fewer productivity improvements than estimated; (12) financial market risks that may affect the Company's funding obligations under defined benefit pension and postretirement plans; (13) the Company's credit ratings and its cost of capital; (14) tax-related external conditions, including changes in tax rates, laws or regulations; (15) matters relating to the proposed spin-off of the Company's Health Care business, including whether the transaction will be completed, or if completed, will be on the expected terms; the risk that the expected benefits will not be realized; the risk that the costs or dis-synergies will exceed the anticipated amounts; the ability to satisfy the various closing conditions; potential business disruption; the diversion of management time; the impact of the transaction (or its pendency) on the Company's ability to retain talent; potential impacts on the Company's relationships with its customers, suppliers, employees, regulators and other counterparties; the ability to realize the desired tax treatment (including whether an Internal Revenue Service private letter ruling will be sought or obtained); the risk that any consents or approvals required will not be obtained; risks associated with financings that may be undertaken and indebtedness that may be incurred in connection with the transaction; and (16) matters relating to the voluntary chapter 11 proceedings of the Company's subsidiary Aearo Technologies and certain of its affiliates (the "Aearo Entities"), including legal risks related to the chapter 11 proceedings; potential impacts to the Company's reputation and its relationships with customers, suppliers, employees, regulators and other counterparties and community members; potential impacts to the Company's liquidity or results of operations, including risks related to the amount that will be necessary to fully and finally resolve all of the Company's obligations to make payments to resolve such claims under the terms of its funding and indemnification agreement with the Aearo Entities; and the Aearo Entities' ability to navigate the chapter 11 proceedings to obtain approval and consummation of a plan of reorganization. Changes in such assumptions or factors could produce significantly different results. A further description of these factors is located in the Reports under "Cautionary Note Concerning Factors That May Affect Future Results" and "Risk Factors" in Part I, Items 1 and 1A (Annual Report) and in Part I, Item 2 and Part II, Item 1A (Quarterly Reports). The Company

assumes no obligation to update any forward-looking statements discussed herein as a result of information or future events or developments.	new